We demonstrate significant improvements in each of the three CAMPHORsubdomains with PAH therapy, alongside improvements in objective measures of PAHtreatment response: functional class, exercise capacity and NTproBNP level. This evidence concerns the gene NPPB and pulmonary arterial hypertension.